Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma
NCT05520814Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Aug 2018
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, camrelizumab, tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sichuan Cancer Hospital. Status: unknown.
02
Drugs
toripalimabcamrelizumabtislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05520814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520814.